Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design
María T. Abreu(Icahn School of Medicine at Mount Sinai), Juli Tomaino(United States Food and Drug Administration), Stephen B. Hanauer(Northwestern University), Walter Reinisch(Medical University of Vienna), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Robert H. Riddell(Mount Sinai Hospital), William J. Sandborn(University of San Diego), Dermot McGovern(Salford Royal NHS Foundation Trust), Julián Panés(Hospital Clínic de Barcelona), Fabio Cataldi(Pfizer (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Brian G. Feagan(Western University), David T. Rubin(University of California System), Swati Tole, Johannes Spleiss, Geert D’Haens(Amsterdam University Medical Centers), Christopher Leptak, Richard Strauss, Andrew E. Mulberg, Péter L. Lakatos(McGill University), Asit Parikh, Vipul Jairath(Western University)
Cited by 29
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Crohn's disease
|The Lancet|2012|2.1k